Clinical Trial Detail

NCT ID NCT03527108
Title Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Fox Chase Cancer Center
Indications

lung non-small cell carcinoma

Therapies

Nivolumab + Ramucirumab

Nivolumab

Age Groups: senior adult

No variant requirements are available.